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As reproductive technologies have developed and become more
widespread internationally, an increasing number of infertile couples have
continued to seek reproductive therapy, including in vitro fertilization, either
with their own cells or through cell donation, with the hope that they can start
families. However, these new technologies have caused European governments
to respond in different ways, ranging from an outright ban based on moral and
ethical objections to no restrictions on access to reproductive assistance. As a
result, European countries have erected regulatory structures that often change
drastically and rarely parallel one another.'
Since there is no central regulation of access to reproductive technology,
the evolving legal status of cell donation has created a phenomenon called
"reproductive tourism." Reproductive tourism refers to the practice of citizens
leaving their home country for another in hopes of receiving treatment that has
been banned in their home country, typically for safety or moral reasons.
Although reproductive tourism has long been an issue in Europe, there has been
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1 For example, Italy was one of the last European countries to put any sort of regulation into place,
yet the government implemented one of the most stringent regulations for infertile couples. See,
for example, Rachel Anne Fenton, Catholic Doctrine versus Women's Rghts: The New Italian Law on
Assisted Reproduction, 14 Med L Rev 73 (2006).
2 Guido Pennings, Legal Harmonization and Reproductive Tourism in Europe, 19 Human Reproduction
2689, 2690 (2004).
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an even greater influx in recent years as the regulations of countries within the
European Union have begun to diverge even more.'
As a general matter, national regulation of reproduction is not particularly
troubling. With such a spread of regulatory schemes, though, the question arises
whether European citizens would benefit if countries submitted to centralized
regulation by the EU. Currently, the EU only regulates the specific guidelines
concerning the quality of cells to be used for transplantation and the ethical rules
for compensating donors.4 Since this regulation is so narrow, countries are free
to generate their own policy concerning which citizens can actually access this
technology. Consequently, a country's ability to deny citizens reproductive
therapies could result in unequal application of the EU's public health directives
because countries with reproductive technologies compete for patients, resulting
in unequal access to quality care. Accordingly, this inequality raises the question
whether the EU should define the reproductive policy of its Member States.
As such, this Development will focus on the role that the EU can and
should play in administering the reproductive technology needs of its Member
States. First, this Development will delve into the specific problems that have
arisen from lack of central regulation.' The discussion will then turn to current
EU regulation practices of donated cell material and how these initiatives are
insufficient to confront the public health problems produced by reproductive
tourism. Finally, the argument concludes by discussing how the EU can
administer cell donations more effectively and in a manner that is more
consistent with its other bioethical practices without infringing on the ethical
concerns of the individual Member States. Overall, this Development will show
that, although individual policymaking has historically been left to the discretion
of the Member States, the unique challenges of ensuring public health norms for
all Europeans require more integrated harmonization of scientific practices in
individual countries. However, this harmonization does not necessarily need to
offend Member States' ethics because countries would still decide whether or
not to offer cell donation as a reproductive option. Rather, instead of ignoring
reproductive tourism, a Directive from the EU would acknowledge that a
3 See, for example, Fenton, 14 Med L Rev at 74 (cited in note 1) (stating that, with stricter Italian
laws preventing couples from reproducing, more citizens must seek treatment abroad).
4 Council Directive 2004/23/EC, 2004 OJ (L 102) 48.
5 Although the reproductive technologies in question range from basic artificial insemination to
surrogate motherhood, this Development's discussion of "reproductive technologies" refers to
any alternative treatment that is sought by an individual or a couple to become pregnant, either
with their own cells or donor cells. In particular, the argument will focus on the particular
problem of cell donation, but the arguments presented here are applicable to the wider range of
reproductive therapies that exist.
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market has developed for cell donation. By regulating this market, the EU would
instill greater confidence in patient safety.
II. REPRODUCTIVE TOURISM AND THE CURRENT
POLITICAL ATMOSPHERE
Reproductive or infertility tourism usually refers to "the movement of
citizens to another state or jurisdiction to obtain specific types of medical
assistance in reproduction that they cannot receive at home."6 Reproductive
tourism occurs for a variety of reasons. People may have to seek out cell
donations and in vitro treatment elsewhere because these treatments are
unavailable, due to general lack of medical expertise in cell donation, laws that
have banned cell donation because it is adjudged to be unsafe, long waiting lists
in the home country, or lower costs abroad
Reproductive tourism is not a new phenomenon in the EU.8 Ever since
biotechnology began introducing new ways for couples to become pregnant,
countries have reacted very differently to regulating both the procedures
themselves and the groups of people who could secure such treatment.9
Although there is obvious variation between laws, the countries' approaches
have been classified in four ways.10 First, some countries are "designing by non-
decision." Often seen as having the most liberal regimes, these countries actually
have such severe fragmentation of ethical viewpoints that compromise for an
appropriate system cannot be reached, and as a result there is little to no
regulation. Second, other moderate countries are considered "designed by
experts" because similarity of moral ideas has essentially encouraged national
legislatures to depend upon the dominant medical beliefs of the time. The third
approach is to "design by mobilization and consultation," which essentially
entails legislative groups who agree that restrictive regulations are necessary.
6 Pennings, 19 Human Reproduction at 2690 (cited in note 2).
7 Tamara K. Hervey and Jean V. McHale, Health Law and the European Union 146 (Cambridge 2004)
(citing Guido Pennings, Reproductive Tourism as Moral Pluralism in Motion, 28 J Med Ethics 337
(2002)).
8 In fact, some commentators have noted how reproductive tourism is becoming an increasingly
global phenomenon. See id at 146. The problem has been especially heightened in Europe,
though, given the array of legislation that continues to arise both to keep pace with the advances
in science and to address ethical concerns. Id at 146-47.
9 For an enlightening discussion of each country's legislative reactions within the European Union,
see generally Christine Rothmayr, et al, Comparing Pok' Design Across Countries: What Accounts for
Variation in ART Poli?, in Ivar Bleikhe, Malcolm L. Goggin, and Christine Rothmayr, eds,
Comparative Biomedical Poliq: Governing Assisted Reproductive Technologies 228, 229-53 (Routledge
2004).
10 Id at 250-51.
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Finally, "design by party politics" evolved in countries where, although beliefs
did not appear to be similar, legislative compromises emerged because of a
shared belief for the need for state responsibility and a general leaning towards
restrictive policy preferences.
Not surprisingly, these different legislative atmospheres have created varied
reproductive regulatory structures within each Member State. Some countries,
like Belgium, have policies which essentially reflect a design that only creates
authorizations for practice and little else. 1 As such, "governance is largely
private, [and] market forces play an important role. . ,,." By contrast, other
countries, like Germany, Norway, and Switzerland, have created regimes that
strictly limit access to reproductive therapies while simultaneously prohibiting
many techniques, including egg donation, pre-implantation diagnostics, and
embryo donation. 3 Not surprisingly, Germany has often had concerns with
citizens leaving for Belgium to seek reproductive assistance.'
4
Although there have always been divergent approaches to regulating
reproductive therapy and other biotechnologies amongst the Member States, the
legal status of the procedures seemed stable. The EU only intervened in what
appeared to be extreme situations. For example, when Germany required
mandatory gynecological exams on women returning to the country from
Belgium, the EU effectively stopped this practice in 1991.1' On the whole,
however, the EU has abstained from direct legislation that would require
countries to have particular procedures or to require access to reproductive
therapies. These moral and ethical judgments have traditionally been left to
countries, and the EU has remained steadfast in this position.
16
The EU's silence on this issue has recently begun to take a toll on the
relative stability of reproductive tourism in Europe. Since there is no central
structure with established guidelines for moderating access to reproductive
technologies, countries have been free to change their governing regimes in
rapid and sometimes unpredictable ways. The most recent example of a major
political shift occurred in Italy. Long considered to be one of the most liberal
countries for its lack of regulations, the source of Italy's lax laws was the
country's severe fragmentation in beliefs regarding regulating assisted
reproduction. The result was a widely unregulated industry due to an interrupted
11 Id at 231.
12 Id at 232.
13 Id at 229.
14 Pennings, 19 Human Reproduction at 2691 (cited in note 2).
15 Id.
16 See, for example, Council Directive 2004/23/EC at 49-50 (cited in note 4).
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design process. 7 Although this flux was well-known throughout Europe and
many laws had been proposed in Italy to ban or to encumber access to
reproductive therapies, including cell donation, few anticipated that Italy would
actively regulate access to reproductive technology. However, in 2004, the Italian
government essentially reversed its permissive position and passed legislation
that severely limited access to new reproductive methods, even in the face of
strong disapproval from its secular and female public. 8 Not only did Italy reduce
the number of assisted reproductive technologies available to its citizens, it also
drastically reduced the number of people who could receive these technologies
by limiting them to heterosexual, committed couples. 9 This change will
undoubtedly force increasing numbers of people to leave Italy to seek out
alternative treatment.
20
The situation in Italy reveals the reality of the delicate balance that exists
within European countries. As countries attempt to parse out and to adapt to
the scientific realities of reproductive therapies, the state of reproductive tourism
will be thrown into an unmanageable state of flux. As one country creates more
stringent standards, another will be forced to absorb the surge of patients. To
date, the Member States of the EU have only dealt with reproductive
technologies on a national level and have not taken steps to address the larger
problems created by reproductive tourism. In addition, most problems of
regulation have arisen between the Western European and Scandinavian
countries. Some concern has been raised that, as Central European states
become more involved in the reproductive market, the variety of regulatory
schemes will only multiply.2' Therefore, as reproductive regimes in the countries
increasingly become unstable, the time is ripe for the EU to moderate the
situation and to prevent long-term public health concerns that are linked with
unregulated reproductive tourism.
17 Rothmayr, et al, Comparing Poliy Design at 234 (cited in note 9).
18 Fenton, 14 Med L Rev at 75-77 (cited in note 1) (discussing the disparity between the secular
public that disapproved of the change and the strong support from the Roman Catholic church);
Italian Lawmakers Enact Rules That Lamit Reproductive Rights, NY Times A16 (Dec 12, 2003).
19 Fenton, 14 Med L Rev at 73 (cited in note 1).
20 Id at 74.
21 Hervey and McHale, Health Law and the European Union at 146 (cited in note 7).
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III. PRESENT REGULATION: DIRECTIVE 2004/23/EC ON
TISSUES AND CELLS
The EU has not completely overlooked regulating cell donation and in
vitro fertilization. The increase in variations in national reproductive policies has
generated considerable discussion about the role that the EU should play in
creating a stable set of reproductive regulations for all of the Member States. In
fact, the general rise of bioscience in many arenas, including genetically modified
food, has created more support for the EU to play a larger role in regulation.22
Accordingly, in 2004, the EU passed Directive 2004/23/EC on Tissues
and Cells ("Directive"). The Directive does not focus solely on reproductive
technology; however, the implications of the Directive effect a minimum
standard of safety and health protocols that Member States must follow when
using donor cells, including using donor cells for reproduction.23 The essential
objective of the Directive is to "lay[ ] down standards of quality and safety for
human tissues and cells intended for human applications, in order to ensure a
high level of protection of human health. ' 24 That is, it establishes standards for
each level of the donation process, including the recruiting of donors, the
storage and distribution of donor cells, and the privacy rights of donors.2' The
Directive does not purport to control the regulation of a patient using his or her
own cells. It only focuses on donations in order to "safeguard public health and
to prevent the transmission of infectious diseases by these tissues and cells,"
advising that in order to do so, "all safety measures need to be taken during their
donation, procurement, testing, processing, preservation, storage, distribution,
and use.'2 6
The Directive focuses more explicitly on acceptable scientific levels of
safety instead of ethical considerations governing reproductive technologies.
This approach is not surprising, given the EU's general trend of relying on
scientific studies to establish guidelines27 and leaving moral and ethical
22 See, for example, Gabriele Abels, Experts, Citizens, and Eurocrats-Towards a Poli Shift in the
Governance ofBiopoliics in the EU, 6 European Integration Online Papers (Mar 12, 2002), available
online at <http://eiop.or.at./eiop/pdf/2002-019.pdf> (visited Nov 17, 2007) (noting the
transition in European politics from civil governance to policy formulation).
23 Council Directive 2004/23/EC at 48 (cited in note 4) ("This Directive should apply to tissues and
cells including haematopoietic peripheral blood, umbilical-cord (blood) and bone-marrow stem
cells, reproductive cells (eggs, sperm), foetal tissues and cells and adult and embryonic stem
cells.").
24 Id at 51.
25 See generally id.
26 Id at 48.
27 Abels, Experts, Citizens, and Eurocrats at 4 (cited in note 22).
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determinations to Member States. The Directive reinforces this position by
making continual declarations to Member States to set stricter standards if
appropriate because the Directive intends to protect the "human rights and
dignity of the human being with regard to the application of biology and
medicine . . . [and] [n]either the Charter nor the Convention makes express
provision for harmonization or prevents Member States from introducing more
stringent requirements in their legislation."28
Although the Directive takes admirable steps in establishing a safety
standard, its own language conflicts with its stated objective. On its surface, it
appears that the EU sets the affirmative safety and quality levels for cell
donation while leaving questions of implementation and ethics to the Member
States. Unfortunately, even though the Directive is an admirable effort, the EU's
desire to leave ethical questions to countries has left gaps in the safety guidelines
regulating cell donation. For example, the Directive strongly encourages
voluntary, nonpaid cell donation because such processes produce safer, higher
quality cells,29 but it does not mandate such measures.30 In addition, there is no
real reporting mechanism that allows the EU to moderate the safety of cell
donation procedures. Rather, the Member States are left to develop their own
penalties for noncompliance with the EU's Directive. Consequently, even
though the EU has set up these particular guidelines, Member States have been
left with so much discretion in their implementation that the level of care can
vary widely amongst the countries, leaving open the potential for public health
standards to dip below the EU's recommended-and more stringent-
guidelines. This problem appears to be coming to fruition. In 2006, the EU
released a study that indicated that one country, Romania, was already moving
away from the voluntary, unpaid donative standard, and donors of reproductive
cells were remunerated.3 2 This study strongly suggests that countries, in order to
28 Council Directive 2004/23/EC, art I at 50 (cited in note 4).
29 Id at 49 ("Voluntary and unpaid tissue and cell donations are a factor which may contribute to
high safety standards for tissue and cells and therefore to the protection of human health.").
30 Id.
As a matter of principle, tissue and cell application programmes should be
founded on the philosophy of voluntary and unpaid donation, anonymity of
both donor and recipient, altruism of the donor, and solidarity between donor
and recipient. Member States are urged to take steps to encourage a strong
public and non-profit sector involvement in the provision of tissue and cell
application services and the related research and development.
31 Id, art 27.
32 See generally Health & Consumer Protection Directorate-General, Report on the Regulation of
Reproductive Cell Donation in the European Union, (Feb 2006), available online at
<http://ec.europa.eu/health/ph-threats/human-substance/documents/tissues-frep-en.pdf>
(visited Nov 17, 2007).
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address the market demands of reproductive tourism, can be swayed to defy
Directive guidelines in order to entice reproductive tourists into their countries
for treatment. This problem will only be inflamed as countries continue to
change their laws, which are becoming increasingly divergent from one another.
Essentially, the EU remains powerless to act for two primary reasons. First,
since the penalty regime does not have specific guidelines, and since the unpaid
donor standard is permissive, the EU cannot enforce standards against the
Member States because none exist. Second, even if the EU had standards to
enforce, it remains in a defensive position because Member States retain the
right to regulate their own activities. The EU can only gain information by
requesting reports from the Member States33 or by asking the Member States to
conduct their own studies.34
As a more general matter, the EU has administered and regulated
biotechnologies before. Regulating reproductive technologies would therefore be
consistent with the administrative role it already plays in other contexts. Because
the EU is not new to biopolitics and governing biotechnologies, it could apply
expertise it has already gained from generating other regulatory structures. For
example, one useful governing approach that has emerged for analyzing EU
biotechnology regulations is to view EU governance as framing biotechnologies
within a market framework. Casting the discussion of biotechnology as one of
markets makes it easier to engage controversial topics by setting a more neutral
tone.35 Discussions about markets are preferable because they "seek[ ] to make
general statements across national boundaries, offering a 'universalizing
discourse' which brings rationality and coherence to a complex and uncertain
issue.' '36 Second, discussing biotechnologies in a market framework realistically
structures the particular problem that the EU is trying to regulate while avoiding
stickier ethical issues.
Thinking about reproductive tourism within a market arrangement
governed by the EU is helpful in establishing consistent safety protocols for cell
donation. Even though reproductive tourism is a clear example of a market
created by differing biotechnology laws, the Member States and the EU
overlook the market created by these laws and focus only on the ethical
33 Council Directive 2004/23/EC, art 26 at 57 (cited in note 4).
34 See, for example, Health & Consumer Protection Directorate-General, Report on the Regulation of
Reproductive CellDonation (cited in note 32).
35 Alan Irwin, The Global Context for Risk Governance, in Belinda Bennett and George F. Tomossy, eds,
Globalization and Health: Challenges for Health Law and Bioethics 71, 77-78 (Springer 2006).
36 Id at 78. It is also important to note, however, that Irwin does not mean to overlook that certain
issues will be emphasized over others in this sort of regime; however, he does at least note that
"economic significance of public attitudes is given great emphasis." Id.
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questions that arise. Acknowledging that reproductive tourism is a market helps
frame the discussion and focus directly on the public health concerns that arise
from a competitive free market in donor cells. By creating a neutral platform
that concentrates on how the market affects patient and cell donation
conditions, the EU can determine where public health defects exist and craft
laws that address specific problems. Otherwise, patient safety standards will
almost certainly suffer. For example, reproductive tourism has been criticized as
creating disparities between the rich and poor, because wealthier couples or
individuals can afford to travel abroad to seek out medical care.3" As a result, as
the market for reproductive technologies emerges, there will be an increased
market temptation not only to continue to cater to the wealthy, but also to create
lower priced medical options for poorer patients. However, it is unclear how
countries could afford to provide lower cost medical services.38 Countries might
also be increasingly tempted to continue to dodge the Directive's requests for
voluntary donations.
IV. CREATING CONSISTENT BIOETHICAL REGULATION IN THE
EUROPEAN UNION
When faced with the challenges of administering guidelines for cell
donation, the problems of reproductive tourism indicate that the EU should
adapt its Directive to confront the present and impending problems of
reproductive tourism. In particular, the EU should take a more central role in
the administration of cell donation to ensure that countries are not tempted by
the market demands to reduce public safety standards. The EU can adapt its
present standard by mandating the use of voluntary donations and by assessing
penalties itself, without relying on the Member States to pass these guidelines
themselves. By expanding its central administrative role, the EU can account for
the full picture of reproductive tourism by widening its bioethical standard to
mandate safer, voluntary cell donation and by becoming the administrative body
that develops penalties for noncompliant states. By doing so, the EU would help
create a more stable environment for reproductive tourism because patients can
be assured that a country engages in safe practices that are consistent with EU
guidelines. If Member States must assess penalties on their own, however,
patients do not have the same guarantee that practices are safe, and the EU does
not have a reliable method for ensuring that countries are compliant.
37 Belinda Bennett, Globalising the Body: Globalisation and Reproductive Rights, 29 U New S Wales L J 266,
270 (2006).
38 Id at 271.
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Expanded EU regulation would not necessarily impinge on the individual
ethical concerns of Member States. Member States could still decide which
practices would be allowed and even who would have access to cell donation
and in vitro fertilization. If a country decided to offer a technology, though, the
Member State would have to submit to stricter regulation by the EU itself so
that the quality of medical care would remain consistent between the countries.
Accordingly, countries like Italy could maintain their ethical position and not feel
compromised by stricter EU enforcement. Essentially, a new, EU-centric
regulation would not be focused on eliminating reproductive tourism. Rather, it
would acknowledge instead of ignore the problems of reproductive tourism and
create a safer atmosphere for helping patients seek treatment without violating
the ethical concerns of their home countries.
In addition, bringing regulation of cell donation under EU administration
is a logical move because the EU has emerged and established itself as an
administrator of biotechnology regulation in other fields. For example, in
developing regulations for genetically modified foods and organisms ("GMOs"),
the EU has effectively dealt with balancing countries' ethical concerns with
public safety concerns. The EU could certainly apply these techniques to
developing effective reproductive regulations.
Admittedly, the development of GMO regulation has been a system of trial
and error; however, the GMO debate has highlighted the importance of three
characteristics for effective EU regulation that are directly applicable to the
problems presented by reproductive tourism. First, the Commission is beginning
to rely more heavily on a science-based model of regulation. It is encouraging a
stronger dialogue between experts and policymakers to create a tighter
connection with science and society.39 This growing dependence on science has
brought the emergence of two additional but closely related factors: the
development of bioethics and the need for social support for technological
innovation. Bioethics has emerged primarily in strategic decisionmaking and
policy creation. Similarly, social support has also played a major role both in
creating a common ground for establishing a baseline of regulation and for more
sensitive governance of GMOs.4° In particular, GMOs became an important
area of policymaking so the European Community could win the trust of the
public to regulate bioethics more safely and effectively.4'
39 Abels, Experts, Ciizens, and Eurocrats at 11-12 (cited in note 22). For a discussion on navigating the
sometimes tumultuous relationship between science and politics, see id at 13-14.
40 Id at 7-8. For a similar discussion on somewhat similar three strands of biotechnology regulation,
see Irwin, The Global Context for Risk Governance at 72-80 (cited in note 35).
41 Abels, Eperts, Citizens, and Eurocrats at 8 (cited in note 22).
Vol. 8 No. 2
Reproducive Tourism and the Role of the European Union Morais
Seen within this context, the gaps in the regulation of reproductive tourism
become clearer. Although the Directive on Tissues and Cells is inclined towards
a science-based model of regulation, it directly overlooks the second and third
factors of bioethics and public discourse. Because the EU has been concentrated
almost exclusively on creating a baseline of safe scientific techniques with little
to no mention of the bioethics involved with such regulation, the door has been
opened for countries to compete with one another directly for patients, thus
creating the market system that threatens the actual viability of the Directive
itself.
Although it would seem that establishment of supranational bioethics
would impinge on a Member State's ability to allow or to ban a procedure,
bioethics for reproductive tourism need not be so broad. Even though these
discussions on the supranational level would raise difficult questions, they are
necessary to the very credibility of the larger EU governance structure, as the
Directive deviations in Romania intimate. Some commentators have even noted
that such discourse is necessary because the commodification of parenting (in
this case, through reproductive tourism) removes parenting from the private
sphere into the public sphere through the large dependence on commercial and
42third party processes.
The EU need not go so far as these commentators theorize, though. The
need for bioethics can emerge from disagreement over a variety of ethical issues,
ranging from arguments concerning who should have access to procedures to
whether the procedures themselves should even be allowed.4 3 Therefore, these
ethical questions do not necessarily need to center on whether the therapies
themselves should be allowed or who should have access to them. Member
States can retain their position as the appropriate platform for making these
decisions. The concern of the EU is more logically contained in what is ethically
acceptable in the procedures themselves. Although the Directive on Tissues and
Cells has directly established strict standards for the acquisition of cells, their
storage, and donor information, it only alludes to how voluntary cell collection
should occur and offers no guidelines on how penalties should be enforced. The
lack of bioethical standards creates the weaknesses inherent in the Directive,
leaving countries with the ability to exploit these gaps in regulating their own
bioethical industries. Accordingly, strengthening these guidelines should be the
42 See generally Jacqueline A. Laing and David S. Oderberg, Artifidal Reproduction, the "WeLfare
Princple," and the Common Good, 13 Med L Rev 328, 338-341 (2005) (discussing the ceding of
dominion from the parent to third party oversight and control). For a wider discussion on the
rights discourse in this area, see Mary Warnock, The Limits of RPghts-Based Discourse, in JR. Spencer
and Antje Du Bois-Pedain, eds, Freedom and Responsibiiy in Reproductive Choice 3, 3-14 (Hart 2006).
43 Tom L. Beauchamp and LeRoy Walters, Contemporary Issues in Bioethics 10 (Wadsworth 6th ed
2003) (describing eight sources of bioethical disagreements).
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EU's first step toward creating a consistent market for reproductive tourism and
holding countries accountable for the health and safety of its cell donations and
its patients.
Overall, the EU's unique position to review the problems presented by
reproductive tourism as a coherent whole cannot be overlooked. Although
individual countries have the right to legislate what is ethically appropriate for
their citizens, the EU also has an ethical obligation to ensure adequate public
health standards for European citizens. It is naive to think that the ethical
considerations of a country can be completely divorced from the ethical
concerns of the EU. However, as reproductive tourism continues to grow as an
unregulated market, the more accountable the EU will need to become for
maintaining acceptable health standards of donors, donor cells, and patients.
Evaluating the conditions of the market, setting stringent safety standards, and
establishing penalties for violating these standards are not only consistent with
the role of the EU, but are necessary to stay in harmony with the EU's goals to
ensure the quality and safety of cells. 44
V. CONCLUSION
Reproductive tourism has become an unmistakable part of the European
landscape. The different policies between the countries will only become
increasingly divergent as rising health costs and public health risks spread
throughout Europe. Since the EU has emerged both as a supranational market
regulator and the principal body for setting scientific standards, regulating
reproductive tourism would be consistent with the present role that the EU
occupies and would not need to interfere with countries' ethical concerns.
Although the EU has traditionally refrained from inserting itself into the
ethics of Member States, regulation of reproductive tourism does not supplant
the individual characteristics of the Member States. The instability inherent
within the regimes of each country is pushing the Member States towards a
potential public health problem, and action by the EU is necessary to prevent
more dire consequences. Francis Fukuyama has acknowledged elsewhere that
although national governing bodies usually fix regulatory issues, that should not
preclude more affirmative action by bodies like the EU:
Regulation seldom starts at the international level; nation states have to
develop rules for their own societies before they can even begin to think
about creating an international regulatory system . . . but there is absolutely
44 Council Directive 2004/23/EC at 48 (cited in note 4).
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no reason to rule out the possibility that it will emerge at this early stage in
the game.45
Within this vein, this Development does not mean to suggest that the EU
should regulate the particular ethical standards of each individual country.
Rather, the EU should focus on how to regulate cell donation and in vitro
procedures that countries have chosen to adopt. Even as countries struggle to
assemble a sensible national policy, the EU can develop its own standards that
reflect public health worries and that could ostensibly offer additional guidance
to countries attempting to grasp how to manage national ethical concerns.
As long as countries diverge over what procedures are morally or ethically
reasonable, citizens of Member States will continue to seek out countries that
can meet their personal needs and desires to begin a family. By failing to
acknowledge that these differing laws have created a market, the EU cannot
effectively govern safe cell donation because countries will always have an
incentive to evade the more permissive aspects of the Directive of Tissues and
Cells. The EU has traditionally filled the role of market regulator and
biotechnological expert well. By combining these two roles, the EU can
effectively govern safe cell donation and create consistent practices that treat
patients-and the laws and practices of the Member States-more equitably
than the current, unregulated regime.
45 Derek Morgan, Regulating the Bio-Economy: A Prehminagy Assessment of Biotechnology and Law, in
Bennett and Tomossy, eds, Globalization and Health 59, 61 (cited in note 35) (quoting Francis
Fukuyama).
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